Low-Dose Maintenance Intravenous Iron Therapy Can Prevent Anemia in Children with End-Stage Renal Disease Undergoing Chronic Hemodialysis

• Published in: International journal of nephrology Vol. 2020; no. 2020; pp. 1 - 8
• Main Authors: Hidayati, Eka Laksmi, Mangunatmadja, Irawan, Tambunan, Taralan, Puspitasari, Henny Adriani, Andriastuti, Murti, Rachmadi, Dedi, Kadaristiana, Agustina, Trihono, Partini Pudjiastuti, Ambarsari, Cahyani Gita, Pardede, Sudung Oloan
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; John Wiley & Sons, Inc; Hindawi Limited
• Subjects: Analysis; Anemia; Anemia in children; Blood; Chronic kidney failure; Drug dosages; Ferritin; Glycosylated hemoglobin; Hemodialysis; Hemoglobin; Iron; Iron deficiency anemia; Kidney diseases; Medical records; Medical research; Medicine, Experimental; Nutritional status; Patients; Pediatrics; Peritoneal dialysis; Statistical analysis; Indonesia; United States > US
• ISSN: 2090-214X; 2090-2158; 2090-2158
• DOI: 10.1155/2020/3067453

Iron deficiency anemia is common in children with end-stage renal disease (ESRD) on long-term hemodialysis receiving erythropoiesis-stimulating agents. One approach to maintain the iron profile and hemoglobin levels is maintenance therapy with regular low doses of intravenous (IV) iron after initial iron repletion therapy; however, evidence for the benefits of this approach is lacking. This study evaluated the effect of IV iron maintenance therapy on anemia in children on regular hemodialysis. This retrospective cohort study included 41 pediatric ESRD patients with normal hemoglobin and iron status who underwent regular hemodialysis at the Pediatric Dialysis Unit of Cipto Mangunkusumo Hospital, Indonesia, between January 2015 and April 2019. Among these, 21 received IV iron maintenance therapy with two doses of 2 mg/kg of IV iron sucrose every 2 weeks (the treatment group) and 20 did not (the comparison group). Changes in hemoglobin and transferrin saturation were assessed after 6 weeks of observation and compared between the two groups. There was a significant reduction in the mean hemoglobin level compared with the baseline level in the comparison group (21 g/L; 95% CI, 9.3–33 g/L; p=0.001) but not in the treatment group (0.7 g/L; 95% CI, −6.6–8 g/L; p=0.84). The risk of anemia was lower in the treatment group (relative risk = 0.42; 95% CI, 0.22–0.79; p=0.003). Although majority of the patients had high baseline ferritin level, this study indicates that in our setting, ferritin may not be a reliable parameter to review the iron status, as it can be affected by chronic inflammation. Hence, the decision to start IV iron maintenance therapy in patients with hyperferritinemia should consider the patient’s clinical condition and morbidity. To conclude, the coadministration of IV iron maintenance therapy is beneficial for maintaining hemoglobin levels and preventing anemia in children with ESRD who are undergoing regular hemodialysis, have achieved the target hemoglobin levels, and have normal iron status.